Treatment of Localized Single-System LCH in Patients Under 18 Years
Clinical Scenario
This protocol addresses Pulmonary Langerhans cell histiocytosis presenting in children and adolescents under 18 years of age with localized single-system disease — specifically a single skeletal lesion (other than CNS-risk lesions) or an isolated cutaneous lesion.
Clinical experience shows that the majority of patients with localized LCH — mostly confined to the skeleton — do not require systemic treatment. Management is guided by lesion characteristics and their risk to the patient.
Treatment Approach
When systemic treatment is warranted — for large, inaccessible lesions at risk of pathologic fracture or permanent sequelae — a mild, short-course systemic regimen following the same approach as used in disseminated LCH may be considered for local disease control.
For isolated cutaneous LCH, systemic therapy may also be considered where topical approaches have not been effective.
The specific agents, sequencing, and full management algorithm are available in the structured protocol.
References
- This document refers to Langerhans cell histiocytosis with onset in childhood and adolescence (age < 18 years).
- Patients with single skeletal lesions other than "CNS-risk lesions" usually do not need systemic treatment (except for large symptomatic lesions or lesions in weight-bearing bones, which are not easily accessible for surgical treatment).
- According to existing clinical experience, the majority of patients with localized LCH (mostly confined to skeleton) do not need systemic treatment.
- In case of large, symptomatic lesions, which are not easily accessible and bear high likelihood for pathologic fractures and permanent consequences, mild systemic treatment of short duration (3-6 months) using the same regimens as in disseminated LCH, may be the preferable option for local disease control.
- Treatment of isolated cutaneous LCH is controversial, but if topical treatments fail, systemic treatment should be considered in infants.